News Releases

Date	Title and Summary	View
Feb 08, 2021	Janssen Presents Results from Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA® (apalutamide) and ZYTIGA® (abiraterone acetate) Combination
Feb 08, 2021	Janssen Announces Treatment with ERLEADA® (apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer
Feb 05, 2021	Johnson & Johnson to Participate in the Cowen 41st Annual Health Care Virtual Conference
Feb 04, 2021	Johnson & Johnson Announces Submission of Application to the U.S. FDA for Emergency Use Authorization of its Investigational Single-Shot Janssen COVID-19 Vaccine Candidate
Feb 03, 2021	Johnson & Johnson to Participate in the Raymond James 42nd Annual Institutional Investors Conference
Feb 02, 2021	JOHNSON & JOHNSON VISION RECEIVES FDA APPROVAL FOR NEXT GENERATION MONOFOCAL INTRAOCULAR LENS - TECNIS EYHANCE™ AND TECNIS EYHANCE™ TORIC II IOLS - FOR THE TREATMENT OF CATARACT PATIENTS
Feb 02, 2021	Janssen to Highlight Robust Solid Tumor Portfolio and Pipeline at 2021 ASCO GU
Feb 01, 2021	Janssen Announces CAR-T Therapy Ciltacabtagene Autoleucel (Cilta-cel) Accepted for Accelerated Assessment in Europe for the Treatment of Patients with Heavily Pretreated Multiple Myeloma
Jan 29, 2021	Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial Vaccine Candidate 72% Effective in the US and 66% Effective Overall at Preventing Moderate to Severe COVID-19, 28 Days after Vaccination 85% Effective Overall in Preventing Severe Disease and Demonstrated Complete Protection Against COVID-19 related Hospitalization and Death as of Day 28 Protection
Jan 27, 2021	Johnson & Johnson to Participate in the Citi's 2021 Healthcare Services, Medtech, Tools, & HCIT Virtual Conference